RxDoctor Payments Data

Jonathan Arbogast, MD

Family Medicine · Clio, MINPI 1326140906

Payments from drug & device makers

$5,525in general payments, 2019–2025

Across 357 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$595
  • Pfizer$548
  • Novo Nordisk$455
  • GSK$448
  • AstraZeneca$373
  • Johnson & Johnson$310
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$5,49599%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,525 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$61,664
Medicare patients
207
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$178,513
TrulicityDulaglutide67$122,599
JardianceEmpagliflozin66$87,665
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$81,524
JanuviaSitagliptin Phosphate54$65,716
MounjaroTirzepatide47$55,292
XareltoRivaroxaban35$37,887
OzempicSemaglutide30$34,600
TradjentaLinagliptin24$34,091
RybelsusSemaglutide17$33,799
MyrbetriqMirabegron37$29,179
LinzessLinaclotide15$22,101
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$21,959
Lantus SolostarInsulin Glargine,hum.Rec.Anlog97$19,999
Nurtec OdtRimegepant Sulfate11$19,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$548$198,310163 claims
Lilly USA, LLCTrulicity, Mounjaro$238$177,891114 claims
Boehringer IngelheimJardiance, Tradjenta$281$121,75690 claims
GSKTrelegy Ellipta$448$81,52483 claims
Novo NordiskOzempic, Rybelsus$455$68,39847 claims
MerckJanuvia$54$65,71654 claims
Johnson & JohnsonXarelto$310$37,88735 claims
Astellas Pharma US IncMyrbetriq$109$29,17937 claims
AbbVieLinzess$595$22,10115 claims
NovartisEntresto$186$18,28713 claims
Sanofi-aventis U.S. LLCLantus$234$4,80413 claims
AstraZenecaSymbicort$373$3,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Clio

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →